Evidence map›Paper›PMID 38715030›Full record

ArticleRespiratory research2024

Increased proportions of circulating PD-1

Jelle R Miedema, Lieke J de Jong, Vivienne Kahlmann, Ingrid M Bergen, Caroline E Broos, Marlies S Wijsenbeek, Rudi W Hendriks, Odilia B J Corneth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Immunopathogenesis of Sarcoidosis.Seminars in respiratory and critical care medicine · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jelle R MiedemaDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands. j.miedema@erasmusmc.nl.
Lieke J de JongDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Vivienne KahlmannDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Ingrid M BergenDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Caroline E BroosDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Marlies S WijsenbeekDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Odilia B J CornethDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.

Funding

Lung Foundation Netherlands 11.1.17.208
6 · The paper itself

Abstract

backgroundThe treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4

methodsWe used multi-color flow cytometry to quantify activation marker expression on PB T cell populations in 22 treatment-naïve patients and 21 healthy controls (HCs). Pulmonary function tests at baseline, 3 and 12 months were used to measure treatment effect.

resultsPatients with sarcoidosis showed an absolute forced vital capacity (FVC) increase of 14.2% predicted (± 10.6, p < 0.0001) between baseline and 3 months. Good response to prednisone (defined as absolute FVC increase of ≥ 10% predicted) was observed in 12 patients. CD4

conclusionsIncreased proportions of circulating PD-1

trial registrationNL44805.078.13.

Indexed as

PrednisoneProgrammed Cell Death 1 ReceptorSarcoidosis, PulmonaryT-Lymphocytes, RegulatoryAdultAgedCD4-Positive T-LymphocytesFemaleGlucocorticoidsHumansMaleMemory T CellsMiddle AgedTreatment OutcomeVital CapacityGlucocorticoidsPDCD1 protein, humanPrednisoneProgrammed Cell Death 1 ReceptorCD25PD-1PrednisoneSarcoidosisT cellsTreatment

Identifiers

PMID38715030
PMCPMC11075187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.